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Background: The exponential increase of individuals aged >64 yrs is expected to impact the
burden of asthma. We aimed to explore the level of asthma control in elderly subjects, and
factors influencing it.
Methods: A multicenter observational study was performed on consecutive patients >64 years
old with a documented physician-diagnosis of asthma. Sixteen Italian centers were involved in
this 6-month project.
Findings: A total of 350 patients were enrolled in the study. More than one-third of elderly
asthmatic patients, despite receiving GINA step 3e4 antiasthmatic therapy, had an Asthma
Control Test score 19, with a quarter experiencing at least one severe asthma exacerbation
in the previous year. Twenty-nine percent of patients (n Z 101) were classified as having96334060.
unige.it (M. Milanese).
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1092 M. Milanese et al.Asthma-COPD Overlap Syndrome (ACOS) due to the presence of chronic bronchitis and/or CO
lung diffusion impairment. This subgroup of patients had lower mean Asthma Control Test
scores and more exacerbations compared to the asthmatic patients (18  4 compared to
20  4, p < 0.01, and 43% compared to 18%, p < 0.01, respectively). Modified Medical Research
Council dyspnea mMRC scores and airway obstruction, assessed on the basis of a FEV1/FVC ra-
tio below the lower limit of normal, were more severe in ACOS than in asthma, without any
difference in responses to salbutamol. In a multivariate analysis, the mMRC dyspnea score,
FEV1% of predicted and the coexistence of COPD were the only variables to enter the model.
Interpretation: Our results highlight the need to specifically evaluate the coexistence of fea-
tures of COPD in elderly asthmatics, a factor that worsens asthma control.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
In high income countries, the prevalence of asthma in older
adults (>64 year) is reported to range between 6% and 10%,
not different from that of young adults [1]. Due to a pre-
dicted 100% increase in people aged >64 years in the next
20 years [2], it is reasonable to expect a rise in the impact
of asthma in older people. Nevertheless, asthma in the
elderly is often underdiagnosed [3] or misdiagnosed [4], and
the mortality for asthma in this age range remains high [1].
Moreover, the burden of concomitant asthma and COPD is
relevant [5], given the reported overlap rate of 40%e60% in
elderly subjects [6]. In particular, the coexistence of
asthma and COPD appears to negatively affect overall
symptom control as well as the response to treatment [7].
Nevertheless, the coexistence of asthma with COPD is still
an exclusion criterion for participating in clinical trials, and
guidelines on this topic are based only on expert opinions.
An important contribution to understanding overlap syn-
drome comes from Spanish investigators who recently
published a consensus document on the clinical phenotype
called “Overlap Phenotype COPD-Asthma” [8]. In partic-
ular, overlap syndrome appears to negatively affect the
response to treatment and overall symptom control.
The mainstay of asthma management is to achieve and
maintain control of the disease. Pharmacological control of
symptoms can be influenced by age-related factors, such as
the more frequent occurrence of comorbidities and pa-
tients having prescriptions for multiple drugs. Comorbid-
ities are considered one of the hallmarks of the geriatric
patient, and they contribute to the complexity of the
elderly and may account for the poorer outcomes of asthma
in this group compared to younger patients. The presence
of comorbidities has been demonstrated to influence
quality of life in adults with asthma [9], which in turn can
affect adherence to treatments. In this context, specific
comorbidities may also impair the ability to use inhalation
devices, for example, in patients who suffer from arthritis.
The impact of comorbidities on elderly asthmatic pa-
tients has never been specifically addressed, especially
with regard to the coexistence of COPD. Herein, we report
the results from the Italian observational study ELderly
Subjects with Asthma (ELSA), which was carried out by a
network of pulmonology and allergy clinics with the aims of
assessing overall asthma control and respiratory function inpatients with and without coexisting COPD, and investi-
gating factors associated with worse control.Methods
The ELSA Survey was carried out between October 2012 and
March 2013 in 16 Italian Health Service pulmonology and
allergy clinics, whose members participated in the task
force promoted by the Allergy Study Group of the Italian
Society of Respiratory Medicine (Societa` Italiana di Medic-
ina Respiratoria, SIMeR). To be consecutively enrolled in
the study, subjects had to have a diagnosis of asthma by a
physician, based on the 2012 GINA guidelines [10], and be
65 years of age or older. Data from each center were
collected by the coordinating center, Pietra ligure (Pul-
monology Division of S. Corona Hospital), which was also
responsible for quality control and final processing of the
data. The study was approved by local Ethics Committees.
For each asthmatic subject, the investigators recorded
the following information using a standardized question-
naire: 1) age, sex, height, and weight; 2) smoking status; 2)
age of asthma onset, defined as the age when the patient
received a physician’s diagnosis of asthma, properly docu-
mented in their medical record; 3) chronic bronchitis sta-
tus, defined as “symptomatic mucus hypersecretion with
cough and sputum daily for at least 3 months over 2 years”
[11]. In addition, patients were given the modified Medical
Research Council (mMRC) dyspnea scale [12] and the
Asthma Control Test (ACT) [13]. Finally, the number of se-
vere asthma exacerbations (SAEs) in the previous year,
defined as “an asthma exacerbation requiring systemic
corticosteroids for at least three days and/or hospitaliza-
tion” [14]; the use of inhaled corticosteroids (ICS) with the
daily dosage expressed as a low, medium, or high dosage of
beclomethasone dipropionate, CFC or equivalent according
to GINA classification [10], and the use of fixed inhaler
combinations (ICS plus Long Acting Beta Agonists, LABA)
were recorded. Comorbidities were inferred by recording
concomitant drug prescriptions for other diseases (arterial
hypertension, chronic heart disease, diabetes, gastro-
esophageal reflux, and osteoporosis). The investigators
were also required to diagnose the occurrence of the
overlap condition (asthma and concomitant COPD) accord-
ing to current guidelines [10,11].
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panel of airborne allergens (grasses, pellitory, ragweed,
birch, cypressus, olive, dermatophagoides pteronyssinus
and farinae, cat and dog epithelia, alternaria tenuis, and
aspergillus fumigatus). The test was considered positive if
the mean wheal diameter was 3 mm or larger after sub-
traction of the mean wheal of the negative control [15,16].
Spirometry (forced vital capacity maneuver) was per-
formed according to the standardized technique [17] after
a proper wash-out period from bronchodilator drugs. In
cases of normal spirometry, a historical reversibility or
methacholine bronchoprovocation test was also obtained to
further support the diagnosis of asthma. In cases where the
airway obstruction defined by the FEV1/FVC ratio was
below the lower limit of predicted values [18], subjects
underwent a second spirometric assessment twenty mi-
nutes after the administration of 400 mcg of salbutamol by
a pressurized metered dose inhaler (pMDI) with a space
chamber. The response was calculated as percentage in-
crease in FEV1 and/or FVC from the baseline value and was
considered “non-significant,” or in the threshold of natural
variability, when the volume increase was <200 ml and
<12% of the baseline value [18]. Moreover, the airway
obstruction was considered to be a “fixed airway obstruc-
tion” when the post-salbutamol FEV1/FVC ratio was below
the lower limit of the predicted value. In cases where FEV1
and/or FVC changed by 200 ml and 12% of the baseline
value, the response was considered “significant,” or above
the threshold of natural variability [18]. Moreover, it was
considered “reversible” if the post-salbutamol FEV1/FVC
ratio reached the normal range, and “nonefully reversible”
when the post-salbutamol FEV1/FVC remained below the
lower limit of normal [19]. All patients with smoking habits
and non-fully reversible airway obstructions, and those
with fixed airway obstructions underwent a single breath
CO diffusion test using the standardized technique [20].
The diffusing capacity of the lungs for CO (DL, CO) was
measured by the single breath method [20] and corrected
for the hemoglobin level. A DL, CO result of <80% of the
predicted value was considered indicative of emphysema in
the absence of anemia or pulmonary fibrosis [18]. Patients
were considered to have asthma-COPD overlap in cases of
chronic bronchitis and/or an impaired CO diffusion test
[11,18] and were referred to as having asthma-COPD
Overlap Syndrome (ACOS).Data analysis
The results are shown as the mean  standard deviation
(SD), unless otherwise stated. With an approximate ex-
pected overlap percentage of 30% between asthma and
COPD in patients aged 65 years [6], 350 subjects were
estimated to be needed in order to include at least 100
subjects with overlap. Continuous variables were compared
using t-tests and dichotomous variables were compared
using a chi-square or Fisher’s exact test. The relationships
between variables were evaluated using Pearson product
moment correlation coefficients. Asthma control was
defined as well-, partially or poorly controlled for ACT
scores of 20, 16e19, or 15, respectively [21]. Multivar-
iate linear regression analyses were performed using theACT score as the dependent variable. A stepwise approach
to model building was applied; the model also included
those variables yielding p-values lower than 0.20 in the
univariate analyses. All tests were two-sided, and p-values
lower than 0.05 were considered statistically significant.
Statistical tests were performed using the Statistical
Package for Social Sciences (version 19.0; SPSS, Chicago,
IL).
Results
A total of 350 elderly subjects with a definite diagnosis of
asthma were enrolled. All patients underwent a forced vital
capacity maneuver. Table 1 summarizes demographic,
clinical and functional data of the study subjects. Those
who had never smoked (69%) were more represented than
former smokers (27%) and current smokers (4%). Fifty
percent of the subjects had a positive skin prick test for
airborne allergens, mainly for house dust mites (HDM, 62%).
There were more females than males (220 vs 130,
p < 0.001), with significant and marked differences be-
tween genders in smoking habits and mMRC scores. With
regard to the outcomes of poor asthma control, an ACT
score of 19 occurred in 39% of the subjects with the
presence of at least one SAE seen in 25%.
Asthma therapy
To better characterize asthma therapy, enrolled subjects
were divided into two groups: a) those enrolled during a
scheduled follow-up visit at the center and named “follow-
up,” and b) those enrolled at their first visit and named
“naı¨ve,” referred by general practitioners at the center for
respiratory symptoms such as exertional dyspnea (44%),
cough (30%), or both (35%), or for a recent “exacerbation”
treated as a “severe asthma exacerbation” (2%). In the
second group, asthma diagnoses were confirmed after a 6-
month follow-up. Fig. 1 shows respiratory drugs recorded at
the time of the enrollment visit for “follow-up” and “naı¨ve”
subjects.
Asthma-COPD overlap syndrome (ACOS)
Twenty-nine percent of asthmatic subjects (n Z 101) were
considered to also be affected by COPD and were classified
as ACOS. Among them, 84% reported chronic bronchitis and
35% demonstrated impaired CO diffusion (54  9% of pre-
dicted, mean  SD). Both conditions were present in 22% of
the subjects. The physician’s diagnosis of asthma-COPD
overlap agreed with the diagnosis based on the above-
mentioned criteria in 92% of cases. When comparing asth-
matics with subjects suffering from ACOS, the latter
appeared to be older and were more frequently former
smokers than asthmatic subjects. Subjects with ACOS did
not differ from those with asthma in the rate of sensitiza-
tion to airborne allergens, except for a higher rate of HDM
sensitization (77% vs 55%, respectively; p < 0.01). Subjects
with ACOS had higher mMRC dyspnea and lower ACT scores
(Table 2). A significantly higher proportion of subjects with
ACOS were shown to have experienced one SAE (43% vs 18%,
p < 0.01) or 2 SAEs (25% vs 7%, p < 0.01) in the previous 12
Table 1 Demographic, clinical and functional data of the study subjects.
All patients (n Z 350) Female (n Z 220) Male (n Z 130) P
Age, yrs 72  6 72  6 73  6 0.590
BMI, kg/m2 27  5 28  5 27  4 0.127
BMI30, % 24 29 17 0.009
Current smokers, % 4 5 1 <0.001
Former smokers, % 26 14 46
Never smokers, % 69 79 51
Pack-years 16  12 18  11 15  12 0.300
Age of onset, yrs 57  18 57  19 58  17 0.457
Asthma duration, yrs 15  18 16  19 15  16 0.594
Sensitized, % 52 53 51 0.912
mMRC, score 1.07  0.89 1.19  0.89 0.86  0.85 0.001
Subjects with SAE,% 25 25 26 0.936
ACT, score 20  4 20  4 21  4 0.036
ACT19, % 39 42 35 0.228
FEV1/FVC, % predicted 88  12 88  12 88  13 0.958
FEV1, % predicted 83  20 85  20 81  20 0.081
FVC, % predicted 94  16 95  16 91  16 0.021
Comorbidity, % 72 74 67 0.080
Two comorbidities, % 42 49 30 <0.001
3 comorbidities, % 13 16 8 0.014
Data are expressed ad mean  SD if not otherwise stated. Sensitized: to airborne allergens. mMRC: modified Medical Research Council
dyspnea score; SAE, Severe Asthma Exacerbation. ACT: asthma control test.
1094 M. Milanese et al.months. Subjects with ACOS had lower airway function as
expressed by a lower percentage of predicted FEV1 and FVC
(Table 2), without any difference in asthmatics in the
response to salbutamol for FEV1 (D278  146 ml and
D11  7% vs D283  151 ml and 19  12%, respectively). The
response to salbutamol for FVC was higher in ACOS than inFig. 1 Follow up and naı¨ve subjects respiratory therapies. LAM
mainly as add on therapy (86% and 100% in the two groups, respecasthma only when expressed as a percentage value (15  12
vs 11  7, pZ 0.009, D280  206 ml vs D247  190 ml). The
percentages of subjects with ACOS with fixed airway
obstruction (19%), non-fully reversibility (38%) or revers-
ibility (43%) were not different from that of subjects with
asthma (25%, 26%, and 49%, respectively). The ratio ofA, Long Acting Muscarinic Antagonist. Montelukast was taken
tively).
Table 2 Demographic, clinical and functional data com-
parisons between asthma and Asthma-COPD Overlap Syn-
drome (ACOS).
Asthmatic
(n Z 249)
ACOS
(n Z 101)
P
Female, % 63 63 0.903
Age, years 72  5 74  5 0.014
BMI, kg/m2 28  5 27  5 0.274
BMI30, % 26 21 0.203
Current smokers, % 4 3 <0.001
Former smokers, % 21 40
Never smokers, % 74 56
Pack-years 16  12 16  11 0.970
Age of onset, yrs 57  17 57  21 0.959
Asthma duration, yrs 15  17 16  20 0.491
Sensitized, % 52 52 1.000
mMRC, score 0.99  0.84 1.26  0.98 0.010
ACT, score 21  4 18  4 <0.001
Subjects
with SAE,%
18 42 <0.010
Subjects
with 2 SAEs, %
7 25 <0.010
ACT score 19, % 28 50 <0.0010
FEV1/FVC,
% predicted
89  12 85  11 0.005
FEV1,
% predicted
85  20 78  20 0.001
FVC, % predicted 95  16 91  16 0.016
Comorbidity, % 68 80 0.026
Two
comorbidities, %
41 45 0.633
3
comorbidities, %
12 16 0.383
Data are expressed ad mean  SD if not otherwise stated.
Sensitized: to airborne allergens. mMRC: modified Medical
Research Council dyspnea score; SAE, Severe Asthma Exacer-
bation; ACT: Asthma Control Test.
Table 3 Distribution of drugs for non respiratory diseases
in asthma and Asthma-COPD Overlap Syndrome (ACOS).
Asthma
(n Z 249)
ACOS
(n Z 101)
P
Arterial
hypertension, %
53 66 0.024
Gastroesophageal
reflux, %
30 23 0.152
Osteoporosis, % 18 25 0.140
Diabetes, % 16 20 0.349
Chronic heart
disease, %
15 14 0.869
Asthma control in elderly asthmatics 1095subjects on follow-up versus those on first visit did not
differ between ACOS and asthma (87% vs 83% and 13% vs
17%, respectively). Subjects with ACOS and asthma under-
went similar treatments, with the exception of a more
frequent use of tiotropium (25% vs 3%, respectively;
p < 0.01), a less frequent use of the ICS/LABA combination
(63% vs 82%, respectively; p < 0.001), and with a higher ICS
dosage (30% vs 15%, respectively; p Z 0.04) in the former.
Similarly, the percentage of patients without any treatment
did not differ between subjects with ACOS and asthma (8%
vs 7%, respectively). The percentage of those on high in-
tensity treatments (step 4, high ICS/LABA or medium ICS/
LABA plus montelukast) who achieved control of their
asthma was not different between those with ACOS and
asthma (23% vs 18%, respectively). A non-significant result
was also found for those with ACOS and asthma who had an
ACT score of 19 (14% vs 8%, respectively).
Non respiratory therapies
Subjects with ACOS more frequently took at least one non-
respiratory drug for another disease compared to subjectswith asthma (80% vs 66%, p Z 0.008). The distribution of
comorbidities between the two groups is summarized in
Table 3, showing a less frequent use of drugs for gastro-
esophageal reflux in subjects with ACOS. The percentage of
subjects with two or more comorbidities did not differ
between the two groups (45% vs 41%). None of the subjects
with ACOS and only 3 subjects with asthma were receiving
treatment with a b-blocking medication.
Factors affecting asthma control
A multivariate linear regression analysis was performed
using the ACT score as the dependent variable in a stepwise
fashion to explore which factors influenced the lack of
asthma control in elderly asthmatics. As shown in Table 4,
the only variables that remained significant were the FEV1%
of predicted, mMRC score and occurrence of ACOS.
Discussion
The main findings of our study are: 1) more than one-third
of elderly asthmatic patients had uncontrolled asthma,
despite using GINA steps 3e4 antiasthmatic therapy; 2)
one-third of elderly asthmatics showed features of COPD;
and 3) elderly asthmatics with COPD had worse control of
the disease.
Asthma control
The well-known trend towards poor control of asthma in
the elderly [1] is confirmed in our study by the fact that an
ACT score 19 and one SAE in the previous year was seen in
39% and 25% of subjects, respectively. One of the possible
explanations could lie in the high proportion of cigarette
smoke exposure in elderly asthmatics. In the current study,
almost 30% of the patients were former smokers; their
percentage was significantly lower in females than in
males. However, the relationship between smoking habits
and asthma is not clear. According to some observations
[22], persistent smoking exposure is associated with a
remission of asthmatic symptoms, perhaps because of the
occurrence of a state of “resistant” airways to the inflam-
matory effects of smoke. On the other hand, susceptible
airways lead to avoidance of smoke or quitting smoking. In
this regard, quitting smoking has been associated with the
Table 4 Clinical and functional variables of patients according to asthma control.
Level of asthma control P
Well controlled Partially controlled Poorly controlled
N (%) 184 (61%) 82 (27%) 37 (12%)
Age, yrs 73  5 72  5 72  7 0.860
F, % 58 62 73 0.234
BMI, kg/m2 27.4  5.0 27.4  4.5 26.7  5.5 0.742
BMI30, (%) 23 26 24 0.883
Current smokers, % 4 4 3 0.599
Former smokers, % 29 27 16
Never smokers, % 67 69 81
Pack-years 16  11 18  12 17  14 0.655
Age of onset, yrs 56  17 55  19 49  22 0.096
Asthma duration, yrs 17  16 17  19 23  23 0.118
Sensitized, % 47 54 57 0.437
mMRC, score 0.72  0.71 1.38  0.80 2.03  0.90 <0.001a
Subjects with SAE,% 20 41 40 <0.001b
FEV1, % predicted 87  20 77  19 75  22 <0.001b
FVC, % predicted 97  15 89  15 90  17 <0.001b
ACOS, % 19 43 43 <0.001b
Comorbidity, % 70 80 70 0.172
Two comorbidities, % 40 51 43 0.247
3 comorbidities, % 12 22 11 0.103
Arterial hypertension, % 56 60 59 0.864
Gastroesophageal reflux,% 26 35 27 0.255
Osteoporosis, % 16 28 27 0.057
Diabetes, % 15 21 16 0.469
Chronic heart disease, % 18 16 11 0.557
Data are expressed ad mean  SD if not otherwise stated. Level of asthma control: well, partially and poorly controlled for ACT (asthma
control test) score 20, 16e19, or 15, respectively. Sensitized: to airborne allergens. mMRC: modified Medical Research Council
dyspnea score; SAE, Severe Asthma Exacerbation.
a All the differences between groups are statistically significant.
b Only the difference between well vs partially and well vs poorly controlled are statistically significant.
1096 M. Milanese et al.remission of asthmatic symptoms [23,24]. In the multivar-
iate analysis, however, smoking exposure did not appear to
influence the lack of asthma control (Table 4).
Females were more represented than males, possibly
because of an increased prevalence of female subjects in
the older population due to their increased longevity. In
our study, females reported more breathlessness than
males as measured by the mMRC scale, as also reported by
others [25,26]. They also had significantly lower ACT
scores, another result reported by other studies [27,28],
although a recent paper did not replicate these findings
[29]. However, in the multivariate analysis, gender did not
hold up as an independent variable affecting asthma
control.
It is noteworthy that 39% of our patients had uncon-
trolled asthma despite receiving a high level GINA therapy
(steps 3e4) [10], and only 8% of them were not receiving
any treatment. Possible explanations for the lack of asthma
control in our elderly patients could be the well-known
poor perception of dyspnea in the elderly [30] and/or a
lower adherence to therapy and/or improper use of inhaler
devices [1,3,31,32]. Indeed, the level of dyspnea percep-
tion (as assessed by the MRC scale) was the most significant
factor affecting asthma control in our study population. In a
recent prospective longitudinal study aimed at assessingasthma remission and control, asthma was controlled in
only 28% of patients, while 41% had partially controlled
asthma and 31% had uncontrolled asthma [33]. A 64%
prevalence of uncontrolled asthma in patients over 18 years
of age was also reported by other authors [34]. We are
confident that our patients, who were receiving regular
clinical follow-ups, received proper instruction and were
regularly tested for their inhalation techniques, although
the lung function of our patients was less impaired than
that reported in the Rochester study [35].
Half of the subjects were sensitized to aeroallergens,
mainly HDM. Although asthma in older patients is thought to
be predominantly non-atopic, recent studies report a
sensitization rate ranging from 30 to 75% [36,37], mainly for
indoor allergens [38]. A recent large population study on
asthma prevalence [39] reported a sensitization rate of
approximately 65% in older asthmatics, which is not
significantly different from what is observed in younger
asthmatics. Interestingly, a total of 9% of our study popu-
lation had HDM sensitization and poorly controlled asthma
(ACT  19), becoming potential candidates for anti-IgE
therapy [10]. As suggested by Scichilone et al. [40], eval-
uation of allergic sensitization should be recommended for
elderly asthmatic patients. Another intriguing finding from
our survey is related to the onset of asthma. Most of our
Asthma control in elderly asthmatics 1097patients received a diagnosis of asthma within the previous
10 years, similar to what was reported in the Rochester
study [35]. We are aware of possible recall bias, which
appears less probable in our survey because our patients
had received diagnoses by their physicians and were
receiving regular follow-ups for asthma. This is in contrast
to surveys that use telephone questionnaires or self-
reported diagnoses of asthma.
Asthmatics may demonstrate a fixed airway obstruction
and develop features similar to COPD over time [41,42].
The definition of ACOS is still a matter of debate [8,43], and
the 2014 update of the GINA guidelines, published during
the revision of this manuscript, provides a consensus-based
approach to distinguishing between asthma, COPD, and
ACOS, rather than attempting to create a formal definition
of ACOS [44]. In a recent epidemiological Italian study on
the general population [45], aging was associated with a
marked decrease in the prevalence of diagnosed asthma
and with a marked increase in the prevalence of diagnosed
COPD. According to this study, the percentage of asthma-
COPD overlap was as high as 61% among the asthmatic
subjects who were over 65 years old. Fifteen percent of
North Carolina adults reported a history of COPD and/or
asthma and 2.4% reported both [46]. In our study popula-
tion, ACOS was observed in 29% of patients, which is lower
than the 40% prevalence reported by Soriano et al. [6] and
similar to that reported by Oraka et al. [47].
In our study population, patients with ACOS had worse
asthma control, in terms of an ACT score of 19 or the
occurrence of SAEs in the previous year, compared to
asthmatic patients. Hardin et al. [48] reported worse con-
trol in patients with COPD, when they had a history of
physician-diagnosed asthma, showing a higher exacerbation
rate (33% vs 18%), similar to the exacerbation rate observed
in our study of patients with ACOS. However, the two
studies are not comparable, because we assessed whether
the coexistence of COPD in asthma impairs its control and
not vice versa. According to a recent study [49], chronic
bronchitis is a risk factor for COPD exacerbations, and this
could be an additional explanation for the high prevalence
of exacerbations in our overlap patients.
Finally, the higher prevalence of exacerbations that we
observed in patients with ACOS may be related to comor-
bidities, which were more commonly reported in these
patients (82% vs the 68% observed in asthmatic patients,
p < 0.001, respectively), in agreement with previous re-
ports [46,50]. It is largely accepted that comorbidities in
older patients make managing their asthma a highly
demanding task [51].
Some caveats should be considered in the in-
terpretations of our results. First, we performed the CO
diffusion test only in subjects with fixed airway obstruc-
tions and/or smoking habits. This could underestimate the
ACOS prevalence, in that subjects with smoking habits and
fixed airway obstructions, but normal CO diffusion tests,
could be considered to be affected by COPD and not by
asthma [11]. However, because we found only 6 subjects
with these characteristics, their misclassification can be
considered negligible. Second, we did not assess airway
inflammation (i.e., induced sputum or exhaled nitric oxide
levels in the expired air), which could help to distinguish
COPD from ACOS [52]. Third, we cannot exclude thatchronic coughing and phlegm are simply clinical aspects of
asthma [33,53,54].
In conclusion, we found that more than one-third of
elderly asthmatic patients had uncontrolled asthma,
despite GINA steps 3e4 antiasthmatic therapy. Our results
highlight the need to specifically address the association
with COPD, which was related to worse asthma control.
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